Seribantumab — drug · CancerIndex

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Trials	Jurisdictions	First approval	First trial
All cancers	Phase2	Phase 2	13	—	—	2008-07
Malignant Bladder Neoplasm	Phase2	Phase 2	1	—	—	Sep 29, 2020
Malignant Breast Neoplasm	Phase2	Phase 2	3	—	—	2011-10
Malignant Esophageal Neoplasm	Phase2	Phase 2	1	—

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
NRG1 Expression1
Seribantumab	Malignant Ovarian Neoplasm

Clinical trials

Trials with this intervention (13)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–13 of 13 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04383210	Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors	terminated	Phase 2	54	Elevation OncologyINDUSTRY	4	Apr 3, 2025	clinicaltrials
NCT04790695	Single Patient Protocol for an NRG1 Fusion Positive Metastatic Pancreatic Cancer Patient Using Seribantumab	completed	Phase 2